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I In nt tr ro od du uc ct ti io on n   
Gastric  cancer  is  one  of  the  most  common
gastrointestinal malignancies world-wide, although in
recent decades a decline has been observed in its
incidence and associated mortality [1, 2]. Gastric
cancer is highly heterogeneous morphologically, but
there are two main histotypes of gastric carcinoma:
the glandular (intestinal) type and the isolated-cell type
(diffuse). A proportion of cases displays a mixed
phenotype harbouring in a single tumour of two
histological components (glandular and diffuse) [3, 4]. 
Although the incidence of gastric cancer in older
patients is decreasing, the incidence of gastric cancer
in younger patients and cases with familial clustering
remains quite stable. This suggests that a genetic
predisposition may play an important role in the
pathogenesis of some forms of gastric cancer [5].
About 10% of cases of gastric cancer show familial
clustering [2, 6] but only 1-3% of gastric carcinomas
A Ab bs st tr ra ac ct t
Approximately 10% of gastric cancer cases show familial clustering but only 1-3% of gastric carcinomas arise
as a result of inherited gastric cancer predisposition syndromes. Direct proof that Hereditary Gastric Cancer is
a genetic disease with a germline gene defect has come from the demonstration of co-segregation of germline
E-cadherin (CDH1) mutations with early onset diffuse gastric cancer in families with an autosomal dominant
pattern of inheritance (HDGC). E-cadherin is a transmembrane calcium-dependent cell-adhesion molecule
involved in cell-junction formation and the maintenance of epithelial integrity. In this review, we describe the
frequency and type of CDH1 mutations in sporadic and familial gastric cancer. Further we demonstrate the
functional significance of some CDH1 germline missense mutations found in HDGC. We also discuss the CDH1
polymorphisms that have been associated to gastric cancer. We report other types of malignancies associated
to HDGC, besides diffuse gastric cancer. Moreover, we review the data available on putative alternative candidate
genes screened in familial gastric cancer. Finally, we briefly discuss the role of low-penetrance genes and
Helicobacter pylori in gastric cancer. This knowledge is a fundamental step towards accurate genetic counselling,
in which a highly specialised pre-symptomatic therapeutic intervention should be offered.H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2004; 2(2) 52
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T Ta ab bl le e   1 1. .   S Su um mm ma ar ry y   o of f   t th he e   g ge er rm ml li in ne e   C CD DH H1 1   m mu ut ta at ti io on n   s sc cr re ee en ni in ng g   s st tu ud di ie es s   i in n   f fa am mi il li ie es s   w wi it th h   g ga as st tr ri ic c   c ca an nc ce er r
S St tu ud dy y T To ot ta al l    H HD DG GC C F FD DG GC C F FI IG GC C F FG GC C C CD DH H1 1 C CD DH H1 1 % %   C CD DH H1 1 % %   C CD DH H1 1
o of f    f fa am mi il li ie es s f fa am mi il li ie es s f fa am mi il li ie es s f fa am mi il li ie es s t tr ru un nc ca at ti in ng g m mi is ss se en ns se e m mu ut ta at ti io on ns s m mu ut ta at ti io on ns s
f fa am mi il li ie es s m mu ut ta at ti io on ns s m mu ut ta at ti io on ns s i in n   H HD DG GC C i in n   F FD DG GC C
Guilford et al, 1998 [9] 3 3 0 0 0 3 0 100% 0%
Gayther et al, 1998 [10] 18 10 0 8 0 3 0 30.0% 0%
Richards et al, 1998 [11] 8 8 0 0 0 2 0 25.0% 0%
Guilford et al, 1999 [12] 6 4 2** 0 0 6** 0 100% 100%
Shinmura et al, 1999 [13] 13 3 0 10 0 0 1 33.3% 0%
Yoon et al, 1999 [85] 5 5 0 0 0 0 2 40% 0%
Iida et al, 1999 [86] 14 0 6 6 2 0 0 0% 0%
Keller et al, 1999 [44] 7 2 5 0 0 1 0 50.0% 0%
Avizienyte et al, 2001 [87] 11 5 4 1 1 0 0 0% 0%
Dussaulx-Garin et al, 2001 [88] 1 1 0 0 0 1 0 100% 0%
Humar et al, 2002 [89] 10 7 3* 0 0 5* 0 57.1% 33.3%
Oliveira et al, 2002 [32] 39 11 24 4 0 3 1 36.4% 0%
Yabuta et al, 2002 [26] 17 2 3 0 12 0 1 50.0% 0%
Wang et al, 2003 [27] 78 0 2** 0 76 0 2** 0% 100%
Oliveira et al, 2004 [28] 1 1 0 0 0 1 0 100% 0%
Jonsson et al, 2002 [25] 3 3 0 0 0 1 0 33.3% 0%
Oliveira et al, in press [30] 32 9 10 3 10 0 1 11.1% 0%
Keller et al, 2004 [29] 28*** 2 21 5 0 0 1* 0 % 4.8%
Brooks-Wilson et al, in press [31] 34 26 7* 1 0 10 3* 46.2% 14.3%
T TO OT TA AL L 3 32 28 8 1 10 02 2 8 87 7 3 38 8 1 10 01 1 3 36 6 1 12 2 4 40 0. .2 2% % 8 8. .0 0% %
*One FDGC families with a germline mutation
**Two FDGC families with missense germline mutations
*** the numbers of families, not included in Ref. (Keller et al 1999) are listed
arise  as  a result  of  an  inherited  gastric  cancer
predisposition syndrome [7]. 
In formulating a definition of familial gastric cancer
syndromes, a distinction must be made between the
histopathological subtypes (diffuse or diffuse with
glandular component/mixed versus intestinal) which
segregate within families [8]. Gastric cancer was proved
to be an inherited disease, primarily in families with
aggregations of diffuse gastric cancer. 
The syndrome of hereditary diffuse gastric cancer
(HDGC) was defined by the International Gastric Cancer
Linkage Consortium (IGCLC) [8], as any family that fits
the following criteria: (1) two or more documented cases
of diffuse gastric cancer in first/second degree relatives,
with at least one diagnosed before the age of 50, or (2)
three or more cases of documented diffuse gastric cancer
in first/second degree relatives, independently of age.
The identification of the germline gene defect underlying
HDGC came from segregation studies in early onset
diffuse gastric cancer families [9-12]. Germline mutations
of the CDH1 gene (EMBL/GenBank Data Libraries#
CDH1 – Z13009) resulting in E-cadherin inactivation
have been identified in HDGC (OMIM# Gastric cancer
– 137215). Families with aggregation of gastric cancer
and index cases with diffuse gastric cancer but not
fulfilling the IGCLC criteria for HDGC are termed familial
diffuse gastric cancer (FDGC). 
The criteria to define hereditary intestinal gastric
cancer (HIGC) families were adjusted by the IGCLC
depending on the incidence of gastric cancer in theH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2004; 2(2) 53
Genetic Screening for Familial Gastric Cancer
T Ta ab bl le e   2 2. .   D De et ta ai il ls s   f fr ro om m   a al ll l   t th he e   C CD DH H1 1   g ge er rm ml li in ne e   m mu ut ta at ti io on ns s   d de es sc cr ri ib be ed d   t to o   d da at te e   i in n   f fa am mi il li ia al l   g ga as st tr ri ic c   c ca an nc ce er r
C CD DH H1 1 M Mu ut ta at ti io on n G Ge en ne e   l lo oc ca at ti io on n M Mu ut ta at ti io on n   t ty yp pe e P Pr re ed di ic ct te ed d   p pr re em ma at tu ur re e    R Re ef fe er re en nc ce e
s st to op p   c co od do on n
45insT Exon 1 Frameshift Codon 32 Oliveira et al, 2002 [32]
49-2A>G Intron 1 Splice-site Unknown Richards et al, 1999 [11]
53delC Exon 2 Frameshift Codon 32 Humar et al, 2002 [89]
59G>A Exon 2 Nonsense (W20X)  Codon 20 Richards et al, 1999 [11]
70G>T Exon 2 Nonsense (E24X)  Codon 24 Guilford et al, 1999 [12]
185G>T Exon 3 Missense (G62V)  Ns Shinmura et al, 1999 [13]
187C>T Exon 3 Nonsense (R63X)  Codon 63 Gayther et al, 1998 [10]
190C>T Exon 3 Nonsense (Q64X)  Codon 64 Guilford et al, 1999 [12]
283C>T Exon 3 Nonsense (Q95X)  Codon 95 Dussaulx-Garin et al, 2001 [88]
372-377delC Exon 3 Frameshift Codon 249 Keller et al, 1999 [44]
382delC Exon 3 Frameshift Codon 215 Brooks-Wilson et al, in press [31]
531+1G>A Intron 5 Splice-site Unknown Brooks-Wilson et al, in press [31]
586G>T Exon 5 Nonsense (G196X)  Codon 196 Guilford et al, 1999 [12]
731A>G Exon 6 Missense (D244G)  Ns Yoon et al, 1999 [85]
832G>A Exon 6 Frameshift Codon 281 Oliveira et al, 2002 [32]
Codon 336+18bp int 7
892G>A Exon 7 Missense (A298T)  Ns Brooks-Wilson et al, in press [31]
1003C>T Exon 7 Nonsense (R335X)  Codon 335 Jonsson et al, 2002 [25]
1008G>T Exon 7 Splice-site Codon 349 Guilford et al, 1998 [9]
1018A>G Exon 8 Missense (T340A)  Ns Oliveira et al, 2002 [32]
1064insT Exon 8 Frameshift Codon 393 Brooks-Wilson et al, in press [31]
1135del8ins5 Exon 8 Splice-site Codon 386 Oliveira et al, 2004 [28]; 
Brooks-Wilson et al, in press [31]
1137+1G>A Intron 8 Donor splice-site Unknown Guilford et al, 1999 [12]
1212delC Exon 9 Frameshift Codon 417 Brooks-Wilson et al, in press [31]
1226T>C Exon 9 Missense (W409R)  Ns Brooks-Wilson et al, in press [31]
1243A>C Exon 9 Missense (I415L)  Ns Wang et al, 2003 (two families) [27]
1460T>C Exon 10 Missense (V487A)  Ns Yoon et al, 1999 [85]
1472insA Exon 10 Frameshift Codon 536 Oliveira et al, 2002 [32]
1476delAG Exon 10 Frameshift Codon 547 Brooks-Wilson et al, in press [31]
1487del7 Exon 10 Frameshift Codon 556 Guilford et al, 1999 [12]
1565+1G>T Intron 10 Splice-site Unknown Humar et al, 2002 [89]
1588insC Exon 11 Frameshift Codon 536 Guilford et al, 1999 [12]
1710delT Exon 11 Frameshift  Unknown Humar et al, 2002 [89]H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2004; 2(2) 54
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T Ta ab bl le e   2 2. .   
1711insG Exon 11 Frameshift  Codon 587 Gayther et al, 1998 [10]
1711+5G>A Intron 11 Splice-site Unknown Brooks-Wilson et al, in press [31]
1779insC Exon 12 Frameshift Codon 604 Brooks-Wilson et al, in press [31]
1792C>T Exon 12 Nonsense (R598X)  Codon 598 Gayther et al, 1998, Humar et al, 2002 [10,89]
1901C>T Exon 12 Missense (A634V)  Codon 653 Oliveira et al, in press [30]
2061delTG Exon 13 Frameshift Codon 783 Brooks-Wilson et al, in press [31]
2095C>T Exon 13 Nonsense (Q699X)  Codon 699 Guilford et al, 1998 [9]
2195G>A Exon 14 Missense (R732Q)  Ns Brooks-Wilson et al, in press [31]
2295+5G>A Intron 14 Splice-site Unknown Humar et al, 2002 [89]
2310delC Exon 15 Frameshift Codon 783 Brooks-Wilson et al, in press [31]
2382-2386insC Exon 15 Frameshift Codon 349 Guilford et al, 1998 [9]
2396C>G  Exon 15 Missense (P799R)  Ns Keller et al, 2004 [29]
2494G>A Exon 16 Missense (V832M)  Ns Yabuta et al, 2002 [26]
population. Thus, countries with a high incidence like
Japan and Portugal should use the diagnostic criteria
analogous to the Amsterdam criteria for HNPCC [13]:
(1) at least three relatives should have intestinal gastric
cancer and one of them should be a first degree
relative of the other two; (2) at least two successive
generations should be affected; (3) in one of the
relatives, gastric cancer should be diagnosed before
the age of 50. In countries with a low incidence (USA,
UK) HIGC was defined as (1) at least two first/second
degree relatives affected by intestinal gastric cancer,
one diagnosed before the age of 50; or (2) three or
more relatives with intestinal gastric cancer at any age.
No germline genetic defect has been found to date in
this type of predisposing disease. 
Families with aggregations of gastric cancer and
an index case with intestinal gastric cancer are termed
familial intestinal gastric cancer (FIGC). 
Families with aggregation of gastric cancer, but
without histology available on the tumours are termed
familial gastric cancer (FGC). 
Patients who developed gastric cancer at an early age
(< 50 years old) without a familial history of gastric cancer
were considered early onset gastric cancer patients. 
T Th he e   C CD DH H1 1   g ge en ne e
E-cadherin is a 120 kD glycoprotein localised at
adherens junctions of epithelial cells, where it mediates
homophilic calcium-dependent cell-adhesion [14, 15].
The CDH1 gene maps to 16q22.1, comprises 16 exons
spanning approximately 100 kb of genomic DNA which
are transcribed into a 4.5 Kb mRNA [16]. The E-cadherin
modular structure consists of five extracellular domains
each ~110 aa in length, with conserved calcium-binding
motifs, a transmembrane region and a cytoplasmic
domain, which interacts with filaments of actin through
catenins [17]. Disruption of the E-cadherin complex is
expected  to  induce  loss  of  cell-adhesion  with
a concomitant increased cell invasion [18, 19]. 
E E- -c ca ad dh he er ri in n   a an nd d   s sp po or ra ad di ic c   c ca an nc ce er r
Loss of E-cadherin function is one of the crucial steps
for tumour progression in several types of human cancer.
Despite what has been observed in other types of
epithelial cancers, in which E-cadherin expression is
down regulated without harbouring gene mutations,
namely thyroid, skin, lung, ovary and colon, in sporadic
diffuse gastric carcinoma E-cadherin down regulation is
often associated with gene mutation [20, 21, 22]. CDH1
mutations have been described not only in diffuse gastric
cancers but also in a specific histological type of breast
cancer namely infiltrative lobular breast cancers, another
epithelial cancer in which neoplastic cells are dispersed
in the stromal tissue [23]. Most of the somatic CDH1
mutations found in sporadic diffuse gastric carcinomas
are missense and in-frame deletions [23]. In contrast to
stomach, the mutations found in infiltrating lobular breast
cancers were out-of-frame mutations, causing premature
stop codons. In both models somatic mutations cluster
in exons 7 to 9, in the extracellular domain of the protein. H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2004; 2(2) 55
Genetic Screening for Familial Gastric Cancer
Inactivation of CDH1 in diffuse gastric cancer cell
lines  and  primary  lobular  breast  carcinomas  is
achieved by 2 genetic hits. Infiltrative lobular breast
carcinomas show LOH at the CDH1 locus as a second
hit. But in the majority of diffuse gastric cancer cases
with  CDH1 mutations  it  was  demonstrated  that
hypermethylation  of  the  CDH1 promoter  region
accounts for the inactivation of the second allele [24]. 
M Mu ut ta at ti io on n   o of f   C CD DH H1 1 i in n   H HD DG GC C   
a an nd d   E Ea ar rl ly y- -o on ns se et t   G Ga as st tr ri ic c   C Ca an nc ce er r   
Germline truncating and missense mutations of the
CDH1 gene resulting in E-cadherin inactivation and/or
segregating with the disease have been identified in
hereditary diffuse gastric carcinoma. To date, forty eight
families harbouring CDH1 germline mutations have
been described, 41 HDGC (40%) and 7 FDGC (8%)
(see Table 1 for details) [21, 25-31]. In these families,
45 different CDH1 germline mutations were found and
dispersed along the gene (see Table 2 and Fig. 1 for
details). The majority (76.0%) of these CDH1 germline
mutations are frameshift, splice-site and nonsense
changes resulting in truncated non active proteins.
Guilford et al described for the first time germline
CDH1 mutations  in  a large  percentage  of  New
Zealand Maori HDGC families [9]. Shortly thereafter,
CDH1 germline mutations were described in a broad
range of ethnic backgrounds. CDH1 mutations were
also found in a significant percentage of HDGC
families of European and American origin [21]. In
families of Asian ethnicity no truncating mutations have
been identified to date [21]. In 24% of the families
CDH1 germline missense mutations have also been
reported [26, 27, 29-33]. These missense mutations
are also distributed along the gene, eight germline
missense mutations cluster in the extracellular region
of the protein, one in the transmembrane domain and
two are localised in the intracellular domain of the
protein (see Table 2 and Fig. 1 for details). 
A total of 104 early-onset apparently sporadic
gastric cancer patients were studied for CDH1 germline
mutations. Eighty seven of them had diffuse type or
mixed gastric cancer with a diffuse component. Only
two of the 104 patients had germline CDH1 mutations
(Table 3). These two mutations were identified in
patients with diffuse gastric cancer [29, 33]. 
Initially it was reported that the mechanism of
inactivation of the CDH1 wild-type allele in tumour
cells from HDGC by families was either by promoter
methylation or by somatic mutation [34]. The biallelic
inactivation leads to diminished or absent E-cadherin
immunoreactivity in the neoplastic cells [34]. Recently
it was found in a Caucasian family with a CDH1
germline splice-site mutation in all members affected
by gastric cancer, a CDH1 intragenic deletion of
CDH1, affecting at least exon 8, as the second hit in
one of the tumours [28]. This observation highlights
T Ta ab bl le e   3 3. .   D De et ta ai il ls s   f fr ro om m   C CD DH H1 1   g ge er rm ml li in ne e   m mu ut ta at ti io on ns s   d de es sc cr ri ib be ed d   t to o   d da at te e   i in n   e ea ar rl ly y   o on ns se et t   g ga as st tr ri ic c   c ca an nc ce er r   p pa at ti ie en nt ts s
C CD DH H1 1   M Mu ut ta at ti io on n G Ge en ne e   l lo oc ca at ti io on n M Mu ut ta at ti io on n   t ty yp pe e P Pr re ed di ic ct te ed d   p pr re em ma at tu ur re e    R Re ef fe er re en nc ce e
s st to op p   c co od do on n
1901C>T Exon 12 Missense (A634V)  Codon 653 Suriano and Oliveira et al, 2003 [33]
1619insG Exon 11 Frameshift Codon 547 Keller et al, 2004 [29]
F Fi ig g. .   1 1. .   S Sc ch he em me e   o of f   t th he e   C CD DH H1 1   g ge en ne e   w wi it th h   g ge er rm ml li in ne e   m mu ut ta at ti io on ns s   d de es sc cr ri ib be ed d   t to o   d da at te e   i in n   H HD DG GC C. .   T Tr ru un nc ca at ti in ng g   m mu ut ta at ti io on ns s   a ar re e   s sh ho ow wn n   a ab bo ov ve e   a an nd d   m mi is ss se en ns se e
m mu ut ta at ti io on ns s   b be el lo ow w   t th he e   g ge en ne e. .   S Si ig g: :   s si ig gn na al l   p pe ep pt ti id de e; ;   P Pr re ec cu ur rs so or r: :   p pr ro ot te ei in n   p pr re ec cu ur rs so or r   d do om ma ai in n; ;   T TM M: :   t tr ra an ns sm me em mb br ra an ne e   d do om ma ai in n; ;   C Cy yt to o. .   D Do om ma ai in n: :   p pr ro ot te ei in n
c cy yt to op pl la as sm mi ic c   d do om ma ai in nH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2004; 2(2) 56
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the need of developing experimental protocols to
identify, in the setting of HDGC families, the presence
of germline or somatic intragenic deletions in CDH1,
which are easily missed by mutation detection methods
based on PCR of genomic DNA. 
F Fu un nc ct ti io on na al l   s si ig gn ni if fi ic ca an nc ce e   
o of f   C CD DH H1 1 g ge er rm ml li in ne e   m mi is ss se en ns se e   m mu ut ta at ti io on ns s
The functional significance associated to CDH1
germline  missense  sequence  variants  is  not
straightforward. Moreover, due to the lethal nature of
the disease there are rarely enough available affected
individuals in any family to perform segregation analysis
in families carrying germline missense sequence variants.
The lack of such knowledge represents a major limitation
for the clinical management of these patients and
families. 
To address this problem, a functional in vitro screen
for gastric cancer missense mutations was created [33].
Cell-lines stably expressing the germline E-cadherin
sequence variants were established and their effect on the
protein ability to mediate cell-cell adhesion and suppress
invasion was addressed. To date, we have analysed nine
germline missense sequence variants and showed that
some of these variants cause impaired or reduced cell-cell
adhesion, increased cell motility and invasion, resulting
in a scattered cell morphology and invasive phenotype
similar to that observed in diffuse gastric carcinoma [29,
31, 33, 35-37] (see Table 4 for details). 
In addition, it was shown that the effect of different
E-cadherin  germline  missense  mutations  in  cell
morphology and motility was distinct, demonstrating
the existence of a genotype-phenotype correlation
between  different  E-cadherin  mutations  and  cell
behaviour, likely dependent on the specific E-cadherin
domain affected by each mutation [38]. 
The aforementioned studies indicate that functional
assays should be used as an adjunct in deciding on
the potential pathogenic role of germline sequence
variants, with significant potential to help clinical
counselling of the CDH1 mutation carriers. 
C CD DH H1 1 p po ol ly ym mo or rp ph hi is sm ms s
There  is  an  increasing  number  of  manuscripts
reporting CDH1 sequence variants in gastric cancer
families and also in controls (see Table 5 for details). Two
good examples of these sequence variants are single
nucleotide polymorphisms located at the promoter region
of CDH1, the -347G–>GA and the -160C/A. Both
sequence  variants  were  described  to  affect  the
transcriptional activity of CDH1. 
The -347G–>GA single nucleotide polymorphism
was shown to down regulate the transcriptional activity
of the E-cadherin gene by measuring the promoter activity
of the -347G–>GA polymorphism. The GA allele
decreased  the  transcriptional  efficiency  by  10-fold
(p<0.001) and had a weak transcription factor binding
compared to the G allele [39]. In a case-control study
performed in a Korean population of 170 individuals (28
probands from gastric cancer families and 142 normal
controls)  the  -347G/GA  heterozygous  or  GA
homozygous was associated with FGC patients (p<0.05)
compared with the G homozygous genotype [39]. 
The A-allele of the -160C/A polymorphism was
shown to decrease the transcriptional efficiency by 68%
compared with the C-allele, down regulating E-cadherin
expression [40]. Wu and colleagues [41] suggested that
individuals who have inherited two copies of the A-allele
that reduce transcription of CDH1 may have a decreased
risk  of  developing  gastric  cancer  in  a Taiwanese
population. However, no consistent data has been
reported about the association between the -160C/A
CDH1 sequence  variant  and  gastric  cancer.  In
a case-control study performed in an Italian population
this variant was associated with an increased susceptibility
to diffuse gastric cancer. The frequency of the -160A allele
was significantly higher (P<0.005) in 53 diffuse gastric
cancer cases compared to 70 matched controls. The
odds ratio associated with the A-allele was 2.27 for
CA-heterozygotes (95% CI 1.16-4.44) and 7.84 for AA-
homozygotes (95% CI 2.89-21.24) [42]. However, these
results were not confirmed in a large series of gastric
cancer patients and control populations from Portugal,
T Ta ab bl le e   4 4. .   F Fu un nc ct ti io on na al l   c ch ha ar ra ac ct te er ri iz za at ti io on n   o of f   m mi is ss se en ns se e   m mu ut ta at ti io on ns s   f fo ou un nd d
i in n   g ga as st tr ri ic c   c ca an nc ce er r   p pr ro ob ba an nd ds s
C CD DH H1 1 A Ag gg gr re eg ga at ti io on n I In nv va as si io on n P Pa at th ho og ge en ni ic c
C Co on ns st tr ru uc ct t s si ig gn ni if fi ic ca an nc ce e
Wild type Yes No Not applicable
A298T No Yes Yes
T340A No Yes Yes
W409R No Yes Yes
A592T Yes No No
A617T Yes No No
A634V No Yes Yes
R732Q No Yes Yes
P799R No Yes Yes
V832M No Yes YesH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2004; 2(2) 57
Genetic Screening for Familial Gastric Cancer
Canada and Germany who have found no significant
evidence for an association between stomach cancer and
the -160C/A polymorphism in the promoter of CDH1.
In this report a total of 899 individuals (433 patients and
466 controls) were analysed. The genotype frequencies
did not differ significantly between cases and controls,
and the genotype-specific risks were not significantly
different from unity, with an odds ratio for heterozygotes
compared with the common homozygote of 1.3 (95%
CI 0.98-1.8) and 1.2 (0.68-2.0) for rare homozygotes
compared with common homozygotes [43]. 
In summary, it is mandatory to clarify the functional
T Ta ab bl le e   5 5. .   P Po ol ly ym mo or rp ph hi is sm ms s   i id de en nt ti if fi ie ed d   i in n   C CD DH H1 1   i in n   g ga as st tr ri ic c   c ca an nc ce er r   p pr ro ob ba an nd ds s   a an nd d   n no or rm ma al l   c co on nt tr ro ol ls s   r re ep po or rt te ed d   t to o   d da at te e
S Se eq qu ue en nc ce e    G Ge en ne e    C Co od do on n E Ef ff fe ec ct t % %   p pa at ti ie en nt ts s % %   c co on nt tr ro ol ls s R Re ef fe er re en nc ce e
v va ar ri ia an nt t l lo oc ca at ti io on n
-71C>G Promoter Unknown 1/13 (7.7%)  2/51 (3.9%)  Avizienyte et al, 2000 [87]
-160C>A Promoter See text 17/32 (53.1%) 63/114 (55.3%) Oliveira et al, 2002 [32]
2/5 (40%)  38/94 (40.4%) Humar et al, 2002 [89]
7/28 (25%) 32/142 (22.5%) Shin et al, 2004 [39]
31/87 (35.6%)  18/50 (36%) Wang et al, 2003 [27]
-347G>GA Promoter See text 12/28 (42.9%) 39/142 (27.5%)  Shin et al, 2004 [39]
48+6T>C Intron 1 Unknown 5/13 (38%)  18/51 (35%) Avizienyte et al, 2000 [87]
11/28 (39.3%)  27/100 (27%)  Oliveira et al, 2002 [32]
1/10 (10%)  75/350 (21.4%) Humar et al, 2002 [89]
5/17 (29.4%)  nd Yabuta et al, 2002 [26]
531+10G>C Intron 4 Unknown 2/34 (5.9%)  nd Oliveira et al, 2002 [32]
ns nd Guilford et al, 1999 [12]
ns nd Gayther et al, 1998 [10]
532-18C>T Intron 4 Unknown 2/66 (3.0%)  0/100 (0%) Suriano and Oliveira et al, 2003 [33]
2/34 (5.9%)  1/50 (2.0%) Keller et al, 2004 [29]
918C>T Exon 7 306 Silent 1/34 (2.9%)  nd Oliveira et al, 2002 [32]
1029C>G Exon 8 343 Silent 1/34 (2.9%)  nd Oliveira et al, 2002 [32]
1774G>A Exon 12 592 A592T 1/34 (2.9%)  1/50 (2.0%)  Keller et al, 2004 [29]
1849G>A Exon 12 617 A617T 2/66 (3%)  2/193 (1%)  Suriano and Oliveira et al, 2004 [33]
1896C>T Exon 12 632 Silent 1/34 (2.9%)  5/100 (5%)  Oliveira et al, 2002 [32]
ns nd Gayther et al, 1998 [10]
1937-13T>C Intron 12 Unknown 2/27 (7.4%)  25/100 (25%)  Oliveira et al, 2002 [32]
ns nd Guilford et al, 1998, 1999 [9, 12]
1937-27T>G Intron 12 Unknown ns nd Guilford et al, 1999 [12]
2076C>T Exon 13 692 Silent 8/13 (61.5%)  nd Avizienyte et al, 2000 [87]
15/27 (55.6%) 29/100 (59.0%) Oliveira et al, 2002 [32]
1/5 (20%)  nd Richards et al, 1999 [11]
7/16 (43.8%)  nd Iida et al, 1999 [86]
ns nd Guilford et al, 1998, 1999 [9, 12]
ns nd Gayther et al, 1998 [10]
ns ns Yabuta et al, 2002 [26]
82/87 (94.3%)  48/50 (96%) Wang et al, 2003 [27]
2253C>T Exon 14 751 Silent ns ns Yabuta et al, 2002 [26]
2292C>T Exon 14 764 Silent 1/34 (2.9%)  nd Oliveira et al, 2002 [32]
2634C>T Exon 16 878 Silent 1/34 (2.9%)  nd Oliveira et al, 2002 [32]
nd, Not done; ns, Not specified. H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2004; 2(2) 58
relevance of the A allele in vivo and to disclose the
association of the A/A genotype with GC in larger
epidemiologic studies. 
O Ot th he er r   c ca an nc ce er rs s   i in n   H HD DG GC C   f fa am mi il li ie es s
In the CDH1 positive families, family members show
other types of malignancy besides diffuse gastric cancer.
Breast, colon (namely signet ring cell cancer of the
colon), prostate and ovarian carcinomas have been
shown to occur in families carrying CDH1 germline
mutations suggesting that non-gastric malignancies
can be associated with HDGC [21, 31]. 
Importantly, breast carcinoma, in particular of the
lobular type, has been associated to a positive history
of gastric carcinoma [44]. There was reported a gastric
cancer patient carrying a germline mutation of CDH1
who had a mother affected with bilateral breast
carcinoma at the age of 49 [29]. An overrepresentation
of this tumour type in families with E-cadherin germline
mutations has been demonstrated [45]. In a recent
study, 17 cases of breast cancer were found in families
carrying CDH1 germline mutations, three of which were
histologically confirmed as lobular breast carcinomas.
This data highlights the need for screening of CDH1
germline mutations in families with both types of
malignancy, diffuse gastric carcinoma and lobular
breast carcinoma occurring in the same family. 
F Fa am mi il li ia al l   G Ga as st tr ri ic c   C Ca an nc ce er r   a an nd d   g ge en ne es s
i in nv vo ol lv ve ed d   i in n   o ot th he er r   i in nh he er ri it te ed d   s sy yn nd dr ro om me es s
Gastric cancer might also be seen as part of the
tumour spectrum in other inherited cancer predisposition
syndromes.  In  particular,  gastric  cancer  has  been
identified as part of the HNPCC syndrome [46]. As
a consequence, the tumours of patients with germline
MMR deficiency exhibit a particular phenotype called
MSI-H, characterised by a global instability phenomenon
affecting microsatellite repetitive sequences [47, 48].
The MSI-H phenotype has been extensively used to
pre-screen tumours in cases in which patients should be
analysed for hMLH1 and hMSH2 [47]. Recently, two
tumours from familial gastric cancer probands were
detected with MSI-H (one with HDGC and the other with
familial gastric cancer). In these two probands germline
mutations in hMLH1 and hMSH2 were excluded, though
other mismatch repair genes may be involved [30]. 
Gastric  cancer  has  also  been  recognised  as
a component of other hereditary cancer syndromes,
such as the Li-Fraumeni syndrome [49]. Most of the
cases harbouring germline mutations of the p53 gene
have been found in approximately 70% of the families
with Li-Fraumeni syndrome. Recently, two gastric cancer
families with p53 germline mutations were identified.
One mutation was previously described in a Li-Fraumeni
kindred  and  the  other  was  localised  in  a highly
conserved region of p53 [29, 30] (Table 6). In these
gastric cancer families with p53 germline mutations,
gastric, liver, pancreatic, colon cancers and leukaemia
occurred in different members of the families [29, 30].
The presence of p53 germline mutations in families with
a predominance of gastric cancer strengthens the need
for p53 mutation screening in families with aggregations
of gastric cancer and no CDH1 mutations. 
In addition to HNPCC and Li-Fraumeni syndrome,
stomach cancer can also occur in breast and ovarian
cancer families. Recently, twenty nine families harbouring
gastric and breast malignancies were screened for
germline mutations in BRCA2 and in six of the 29
(20.7%), three frameshift mutations and three missense
mutations were identified [50]. Moreover, a BRCA2
mutation was found in eight of 34 women with ovarian
cancer and a family history of stomach cancer [51]. In
gastric cancer families with an excess of breast and
ovarian tumours, lacking CDH1, p53 or MSI-H tumour
phenotype, BRCA2 is likely to be a candidate gene. 
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TP53 66 471C>G (FGC)  Family reclassified as Li-Fraumeni Oliveira et al, in press [30]
847C>T (FDGC)  Highly conserved residue (Arg 283) Keller et al, 2004 [29]
SMAD4 32 0 Probably not relevant for familial gastric cancer Oliveira et al, in press [30]
Caspase10 32 0 Probably not relevant for familial gastric cancer Oliveira et al, in press [30]
RUNX3 34 0 Probably not relevant for familial gastric cancer Keller et al, 2004 [29]
HPP1 34 0 Probably not relevant for familial gastric cancer Keller et al, 2004 [29]H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2004; 2(2) 59
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O Ot th he er r   c ca an nd di id da at te e   g ge en ne es s   
i in n   F Fa am mi il li ia al l   G Ga as st tr ri ic c   C Ca an nc ce er r   
In kindreds negative for CDH1 or p53 germline
mutations, other genes are probably involved. We will
address RUNX3, HPP1, Caspase-10 and SMAD4, which
have been shown to be involved in gastric cancer
development (mutated in sporadic gastric carcinoma or
associated with gastric cancer phenotype in knockout
models). 
Putative  tumour  suppressor  genes,  which  are
commonly inactivated in sporadic gastric cancers,
could also represent good candidate susceptibility
genes to familial gastric cancer. RUNX3, which belongs
to the family of runt domain transcription factors, as
well as HPP1, encoding a cell surface receptor, which
is suggested to play multiple roles in cell growth,
maturation and adhesion, have recently been shown
to be inactivated by promoter hypermethylation at
a high frequency in gastric cancer [52, 53]. Moreover,
in the Runx3/Pebp2alphaC null mouse gastric mucosa
exhibits hyperplasias due to stimulated proliferation
and suppressed apoptosis in epithelial cells. Gastric
cancer families that were screened for RUNX3 and
HPP1, do not show germline mutations in both genes,
suggesting that RUNX3 and HPP1 are not important
alternative gastric cancer predisposition genes [29]. In
3% of sporadic gastric carcinomas alterations of
caspase-10 were described [54]. In vitro expression
studies have shown that cells carrying caspase-10
mutations harbour impaired caspase-10-mediated
apoptosis, suggesting that somatic alterations of the
caspase-10 gene might contribute to the pathogenesis
of gastric cancers through the loss of their apoptotic
function [54]. Germline mutations in caspase-10 were
recently screened in families with gastric cancer and
early-onset gastric carcinoma patients, but only a high
frequency of sequence variants was found. All variants
showed similar frequencies in cases (gastric cancer
probands) and in control populations demonstrating
its polymorphic nature [30]. 
In knockout studies SMAD4 heterozygous mice
revealed the presence of foci of signet ring carcinoma
cells in the stomach [55]. Germline mutations in the
SMAD4 gene were described in a minority of hereditary
juvenile polyposis (JPS) [56, 57]. The tumour suppressor
gene, SMAD4, is a transcription activator that binds
specific DNA sequences and whose nuclear localisation
is induced after exposure to TGFβ. This gene was
searched for germline mutations in gastric cancer
families but only sequence variants were found. These
sequence variants were either silent or intronic alterations
that were present with the same frequency in normal
controls pointing to its polymorphic nature [30]. 
In  summary,  RUNX3,  HPP1,  Caspase-10 and
SMAD4 can be ruled out as major gastric cancer
predisposition genes in families with an excess of
gastric carcinoma (see Table 6 for details). 
G Ge en ne et ti ic c   c co ou un ns se el ll li in ng g   i in n   H HD DG GC C
The IGCLC recommends pre- and post-test genetic
counselling for families that either meet or exceed the
minimum requirements for HDGC [8]. 
Testing of asymptomatic at-risk adults for HDGC is
available only after an affected family member has been
tested and a mutation found. Testing of an asymptomatic
at-risk individual is considered predictive testing, not
diagnostic testing. Lynch et al [58] describe the genetic
counselling process they followed with a large kindred
with HDGC. Relevant issues should be discussed with
family members seeking predictive testing for HDGC.
Discussion should include: (1) the genetics of cancer
development and HDGC; (2) the individual’s knowledge
of HDGC; (3) the individual’s reasons for requesting the
test; (4) the individual’s understanding of the risk for
having inherited the mutation based on a family history
of HDGC; (5) availability of molecular genetic testing;
(6) cancer risk if the individual has inherited the mutation;
(7)  recommendations  for  cancer  screening  and
prophylactic surgery; and (8) the possible social impact
of positive and negative test results. 
Genetic  testing  in  children  has  always  been
a controversial issue. Since there have been reports of
patients diagnosed with HDGC under the age of 18,
it has been suggested that genetic testing in children
may be beneficial [8]. Overall, a request from parents
for testing of asymptomatic at-risk children requires
sensitivity and understanding and thorough rigorous
counselling for both the parents and child. 
Requests for prenatal testing for conditions such as
HDGC that do not affect intellect and have some
available treatment are uncommon. Differences in
perspective may exist among medical professionals and
in  families  regarding  the  use  of  prenatal  testing,
particularly if the testing is being considered for the
purpose of pregnancy termination rather than early
diagnosis.  Although  most  centres  would  consider
decisions about prenatal testing to be the choice of the
parents, careful discussion of these issues is appropriate. 
H He el li ic co ob ba ac ct te er r p py yl lo or ri i i in nf fe ec ct ti io on n   
a an nd d   F Fa am mi il li ia al l   G Ga as st tr ri ic c   C Ca an nc ce er r
Among the possible causes of familial aggregation of
gastric cancer, exposure to similar environmental factorsH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2004; 2(2) 60
such as H. pylori infection may contribute to a higher
number of affected individuals within the same family. 
H. pylori is one of the most common chronic
infections in a man, and once acquired early in
childhood and if left untreated, persists for the host’s
lifetime [59]. Risk factors for H. pylori acquisition
include  a low  socioeconomic  status,  household
crowding,  country  of  origin  and  ethnicity,  and
transmission occurs from person to person [60].
Intrafamilial clustering of the infection also reinforces
the importance of person-to-person transmission [61]. 
A large number of studies provided evidence for
the aetiological role of H. pylori in gastric carcinoma,
and the infection significantly increases the risk of
developing both subtypes of gastric carcinoma [62-
65]. Despite the well established role of H. pylori as
a risk factor for gastric cancer, the mechanism of
carcinogenesis  is  still  not  very  clear.  The  first
consequence of H. pylori infection is the induction of
chronic  superficial  gastritis.  The  initiation  and
promotion of gastric neoplasia may occur via disruption
of the epithelial cell proliferation/apoptosis balance
and direct damage to host-cell DNA through the
synthesis of reactive oxygen species [66, 67]. 
Nevertheless, only a small fraction of infected
individuals develop gastric cancer. This probably
depends  on  a combination  of  factors,  including
variation  in  bacterial  pathogenicity.  H.  pylori is
genomically diverse and strain differences in virulence
factors, including the cag pathogenicity island and the
vacuolating cytotoxin, have an important role in the
development of gastric carcinoma [68-70]. 
Within the context of familial gastric cancer, it has
been shown that first degree relatives of gastric cancer
patients have an increased prevalence of H. pylori
infection [71-73]. Furthermore, H. pylori-infected first
degree relatives of gastric cancer patients have an
increased prevalence of histological and physiological
preneoplastic changes, such as atrophic gastritis, intestinal
metaplasia and high levels of hypochlorhydria [71, 74]. 
Although it has not been proven that the eradication
of H. pylori will result in protection against gastric cancer
in first degree relatives of gastric cancer patients, this
group is at a significantly higher risk than the general
population  [72,  74,  75].  Therefore,  international
consensus guidelines strongly recommended H. pylori
eradication in first degree relatives of gastric cancer
patients [75]. 
In summary, although familial aggregation of gastric
cancer may be mediated by familial clustering of H.
pylori infection [61], the infection alone cannot explain
all  of  the  family  aggregation  of  gastric  cancer.
Additional genetic and environmental risk factors are
likely to contribute to this finding. 
L Lo ow w   p pe en ne et tr ra an nc ce e   g ge en ne es s
a an nd d   g ge en ne et ti ic c   s su us sc ce ep pt ti ib bi il li it ty y   t to o   g ga as st tr ri ic c   c ca an nc ce er r
The low frequency of germline mutations in high
penetrance genes in familial gastric cancer may be
related to an increased susceptibility of these patients to
gastric cancer due to low penetrance predisposing genes
in association with environmental factors. Patients infected
with H. pylori are at an increased risk of developing
gastric carcinoma [62]. The risk of developing this type
of tumour relates to the physiological and histological
changes that H. pylori infection induces in the stomach
[76, 77]. Although there is evidence showing that H. pylori
infection plays a crucial role in the pathogenesis of gastric
carcinoma, a striking difference exists between the number
of infected individuals and the number that go on to
develop malignancy. Hence, progression towards disease
is likely to depend on the combined effects of bacterial
pathogenicity, host susceptibility and environmental
factors. 
The IL1B-511*T and IL1RN*2 alleles – which are
putatively associated with increased levels of IL1β
production [78, 79] – and the TNFA-308*A allele –
which is thought to increase the production of TNFα
[80] – have been found to confer an increased risk of
development of gastric carcinoma [69, 81, 82]. The
combined effect of pro-inflammatory host genetic
polymorphisms in the IL1B, IL1RN and TNFA genes in
the risk of gastric carcinoma development has also
been investigated. For gastric carcinoma the odds of
developing disease increased with the number of
high-risk genotypes. Individuals carrying the three
high-risk genotypes are at an increased risk of gastric
carcinoma with an OR of 9.7 (95% CI 2.6-36.0) [83].
Very similar findings were also reported by El-Omar
and colleagues [84]. 
Results on record support the hypothesis that the extent
of gastric mucosal injury may be related to H. pylori strain
differences, inflammatory responses governed by host
genetics, and interactions between host and bacterial
determinants. The combination of these factors, favouring
a set of responses with higher magnitude, can eventually
result  in  hypochlorhydria,  corpus  atrophy,  and  an
increased risk of gastric carcinoma. In this context, the
IL1B, IL1RN and TNFA genes would play a role in gastric
carcinogenesis as low penetrance genes. 
I In n   c co on nc cl lu us si io on n
Sporadic diffuse gastric cancer cases harbour somatic
mutations within the CDH1 gene of the truncating and
missense type, clustered in exons seven to nine. Similarly,
approximately 40% of the families that fulfil the criteria
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for HDGC show germline mutations of the same gene,
~ 80% of which are of the truncating type and evenly
distributed along the gene. In ~20% of cases, germline
CDH1 missense  mutations  were  found  and  their
functional significance was determined by functional
assays using an in vitro cell model system. p53 was
found to be mutated in families with an excess of gastric
cancer and negative for CDH1 germline mutations
indicating the need of p53 screen in these types of
families. These p53 germline mutation carriers should
have a distinct clinical follow-up. It is of great importance
to perform an early and comprehensive screening for
CDH1 mutations in families at an increased risk of
developing diffuse gastric cancer, to allow adequate
genetic counselling in these families. Efforts must be
made to disclose the genetic basis underlying HDGC in
families that lack CDH1 mutations. Familial aggregation
of gastric cancer, in the absence of mutations in high
penetrance genes, may be in part explained by familial
clustering of H. pylori infection in combination with an
increased host susceptibility. 
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